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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
1. To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of
HCV infection among people who inject drugs (PWID).
2. To assess the effect of OST alone on the incidence of HCV infection among PWID.
Research questions
1. How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among
PWID?
2. How effective is OST alone for reducing HCV incidence among PWID?
3. How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)?
4. How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)?
5. How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?
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B A C K G R O U N D
Description of the condition
The number of people with hepatitis C virus (HCV) continues to
increase globally, with an estimated 114.9 (91.9 to 148.7) million
people infected with antibodies to HCV (Gower 2014), 3 to 4
million people newly infected each year and 350,000 deaths oc-
curring annually (Mohd Hanafiah 2013; Perz 2006). There were
an estimated 35 million people living with human immunodefi-
ciency virus (HIV) in 2014. Emerging evidence suggests that HIV
transmission has declined since 2001 and more people are being
treated (UNAIDS 2014). Co-infection of HCV among people
living with HIV is a major global public health concern, with an
estimated 4 million people co-infected (Platt 2015).
Evidence shows that injecting with needles/syringes that have been
used by someone else is the main risk factor for infection with
HIV and HCV for people who inject drugs (PWID). Additional
risks for HCV include sharing drug preparation containers, filters
and rinse water, and back loading (a method of sharing drugs by
injecting them from one syringe into the back of another opened
syringe) (Pouget 2012; Strathdee 2010).
Description of the intervention
Needle and syringe programmes (NSPs) are often a first point of
contact for PWID. They provide immediate support to minimise
drug and sexual risk related harms, including the provision of clean
needles/syringes and condoms toprevent the transmissionof blood
borne viruses and bacterial infections, and other adverse health
outcomes. By maximising the amount of clean injecting equip-
ment in circulation, it is possible tominimise the time that infected
equipment remains in use and the proportion of unsafe injections
(Kaplan 1992). NSPs operate through a range of modalities in-
cluding via fixed-sites, outreach, peer PWID networks, vending
machines, and pharmacies. Engaging in behaviours that are so-
cially stigmatised and illegal, PWID have high rates of unemploy-
ment and homelessness, and have frequently been in prison. NSPs
also provide access to longer-term support by engaging with users
to make onward referrals to other much-needed medical, drug
treatment or social support services.
Drug treatment for opiate addiction and dependence also encom-
passes a range of strategies to manage injecting drug use, such as
pharmacological maintenance or detoxification treatment, phar-
macotherapy combined with psychosocial approaches and resi-
dential rehabilitation. The most commonly prescribed forms of
opioid substitution therapy (OST) are opiate agonist treatments:
methadonemaintenance therapy andbuprenorphinemaintenance
treatment . OST is prescribed to dependent users to diminish the
use and effects of illicitly-acquired opiates. It is usually taken orally
and therefore reduces the frequency of injection and unsafe inject-
ing practices (Tilson 2007). Evidence suggests that OST is most
effective when it is continuous and provided at adequate doses
(Amato 2013; Faggiano 2003).
International evidence supports the use of combination interven-
tions to prevent and treatHIV among PWIDwith the provision of
needles/syringe programmes, antiretroviral treatment and opiate
substitution therapy as the cornerstone interventions (Degenhardt
2010). There is good evidence that NSP and OST in combina-
tion reduce injecting risk behaviours, and evidence to show an
impact on HIV incidence; however, evidence of their impact on
HCV incidence among PWID in combination or alone is limited
( Gibson 2001; Gowing 2011; Jones 2011; Palmateer 2010; Van
Den Berg 2007).
How the intervention might work
Two recent systematic reviews of 12 observational studies esti-
mated a moderate effect of NSPs on reducing HIV transmission
by 48% (95% confidence interval (CI) 3% to 72%) and strong
evidence for OST reducing HIV transmission by 54% (95% CI
33% to 68%) (Aspinall 2014; MacArthur 2012). Previous reviews
(Gibson 2001; Tilson 2007; Wodak 2004) have synthesised evi-
dence for the use of NSPs but focused primarily on HIV as the
main outcome and as a consequence failed to include all the avail-
able evidence on HCV (Palmateer 2010).
A recent analysis of pooled data (N = 919) identified through a
systematic review examined the effect of NSP coverage on HCV
incidence, defining coverage in terms of the proportion of injec-
tions with a sterile syringe. This analysis suggested that high cov-
erage of NSP (“100% NSP”, i.e. obtaining ≥ 1 sterile syringe per
injection) or OST (defined as receiving OST or not, either cur-
rently or within the last 6months) can each reduce HCV infection
risk by 50%; and in combination by 80% (Turner 2011). How-
ever, due to a small number of incident HCV cases (N = 40), the
efficacy estimate for 100% NSP among those not on OST was
borderline significant (95% CI 0.22 to 1.12), and there was in-
sufficient power to evaluate whether a dose response relationship
exists. Another systematic review examined evidence drawn from
observational studies on a range of risk reduction interventions in-
cluding behavioural interventions, NSP, and OST on HCV sero-
conversion (Hagan 2011). This study measured the effect of NSP
use, defined inconsistently by available studies as any attendance
at a NSP or attendance at one point in time, and showed increased
risk of seroconversion. Limitations of the available studies that
comprised this review included substantial heterogeneity, and lack
of clarity and consistency in the measurement of NSP use across
studies. That evidence was drawn only fromNorth America limits
the generalisability of findings to other geographic settings.
A previous review on the effect of OST use on HIV transmis-
sion detected many more studies than earlier Cochrane reviews
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(MacArthur 2012). We also expect that not all evidence on the
effect of NSP on HCV transmission has been identified. Extend-
ing previous reviews would strengthen the evidence base, as well
as provide a more refined measure of NSP coverage that accounts
for frequency and degree to which NSPs meet individuals’ require-
ments for sterile drug injection equipment.
Why it is important to do this review
Evidence of the effect of NSP with and without OST on HCV
incidence is inconclusive (Committee on the Prevention of HIV
infection 2007; Mathers 2012). Previous reviews have failed to
define the frequency of use of the intervention and the quantity
of needles/syringes received by injectors (Hagan 2011), and a pre-
vious pooled analysis had an insufficient sample size to accurately
measure the effect (Turner 2011). This review is needed in or-
der to estimate the effect of NSPs using a consistent definition of
coverage, and examining impact with and without OST on HCV
incidence, in order to inform harm reduction policies to reduce
the burden of HCV.
O B J E C T I V E S
1. To assess the impact of needle/syringe programmes with
and without opiate substitution therapy (OST) on the incidence
of HCV infection among people who inject drugs (PWID).
2. To assess the effect of OST alone on the incidence of HCV
infection among PWID.
Research questions
1. How effective are needle/syringe programmes (NSP) with
and without the use of OST for reducing HCV incidence among
PWID?
2. How effective is OST alone for reducing HCV incidence
among PWID?
3. How does the effect of NSP and OST vary according to
duration of treatment (i.e. for NSPs weekly attendance versus
monthly)?
4. How does the effect of NSP vary according to the type of
service (fixed site versus mobile; high coverage versus low
coverage)?
5. How does the effect of OST vary according to the dosage of
OST, type of substitution used and adherence to treatment?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), prospective
and retrospective cohort studies and case-control studies. Prospec-
tive studies that examine HCV incidence in PWID, which may
have collected data regarding NSPs and OST but which have not
reported the data in the published study, or have reported data as
part of an adjusted analysis, will also be included. For these studies,
we will seek unpublished data relating to the impact of NSP/OST
on HCV transmission via contact with study authors. Studies will
only be included if these data are provided.
Cross-sectional surveys will be used if they include a measure of
recent infection through positive ribonucleic acid (RNA) results
on anti-body negative samples. We will exclude cross-sectional
studies (including serial cross-sectional studies) reporting HCV
prevalence.Methods to be used in this systematic review in relation
to the search strategies and approaches to data synthesis follow
methods applied in a similar review to assess the impact of OST
on HIV incidence (MacArthur 2012).
Types of participants
People who inject drugs (opiate and or stimulants). Studies that
include participants undergoing opportunistic HCV testing (out-
side of the study setting) will be excluded, as will those relating
to people who inject drugs in the prison setting, since treatment
provision in this setting will differ significantly to community and
healthcare settings.
Types of interventions
Experimental interventions
• NSP and OST
• NS alone
• OST alone
Studies may be based in a drug treatment facility or in the wider
community, at a fixed site or mobile unit.
• Exposure to NSP will be defined as the proportion of
injections that are covered by a clean needle/syringe. Where it is
not possible to estimate this proportion we will define exposure
accounting for frequency of injection and the degree to which
the NSP meets the individual’s requirement for needles/syringes.
• Exposure to OST will be defined as the continuous or
interrupted treatment, current, recent (past 6 months or
duration of HCV observation period) or any past treatment with
methadone or buprenorphine.
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Control intervention:
• no intervention;
• OST alone.
Types of comparisons
1. NSP with OST versus NSP alone;
2. NSP with OST versus OST alone;
3. NSP with OST versus no intervention;
4. NSP alone versus no intervention;
5. OST alone versus no intervention.
Types of outcome measures
Primary outcomes
Incidence of HCV infection in PWID as measured via repeat
testing such as detection of HCV RNA positive among HCV
antibody negative results or antibody avidity.
Studies will be included if they report a minimum of two HCV
seroconversions (HCV antibody negative to HCV antibody posi-
tive) among the study participants from tests conducted at differ-
ent time points. We will exclude studies relying on self-reported
data for the outcome.
Search methods for identification of studies
Papers will be identified in four ways. Firstly we will conduct two
primary searches of the literature based on key search terms identi-
fied by the review of reviews and recent review of the effect of OST
andNSP on the risk of HIV and HCV among PWID (MacArthur
2012; Palmateer 2010). The purpose of the two searches are to: a)
to identify studies that measure the impact of NSP/OST on HCV
incidence (see Appendix 1) and b) to identify longitudinal studies
that measure HCV incidence and report the impact of NSP/OST
as part of an adjusted analysis (see Appendix 2). The search strat-
egy will be reviewed by the Cochrane Drugs and Alcohol Group
Trials Search Co-ordinator, who will also conduct the search.
Electronic searches
We will search for relevant studies in the following sources:
• the Cochrane Drugs and Alcohol Group’s Specialised
Register of Trials;
• the Cochrane Central Register of Controlled Trials
(CENTRAL, most recent issue);
• the Cochrane Database of Systematic Reviews (CDSR)
(Cochrane Library, most recent issue);
• the Database of Abstracts of Reviews of Effects (DARE)
(Cochrane Library, most recent issue);
• MEDLINE (Ovid) (1966 to present);
• EMBASE (EMBASE.com) (1974 to present);
• Global Health (Ovid) (1974 to present);
• CINAHL (EBSCOhost) (1982 to present);
• Web of Science (1991-to present);
• PsycINFO (Ovid) (1985 to present).
We will search for ongoing clinical trials and unpublished trials
via searches of the following websites:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organisation (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).
Searching other resources
We will search the publications of key international agencies in-
cluding the EuropeanMonitoring Centre onDrugs and Drug Ad-
diction, European Centre for Disease Control, the National In-
stitute on Drug Abuse, the US Institute of Medicine, the United
Nations Office on Drugs and Crime Prevention and the World
Health Organisation. We will handsearch the reference lists of rel-
evant articles to identify additional relevant studies, and contact
experts in the field to identify ongoing research.Wewill also search
conference abstracts including the International Harm Reduction
Conference, International HIV/AIDS Society and the European
Association for the Study of the Liver conference. Finally we will
contact principal investigators and authors of prospective studies
that examine HCV incidence in PWID to collate data regarding
NSPs and OST but which have not reported the data in the pub-
lished study,
There will be no language or date restrictions, and we will include
peer reviewed and non-peer reviewed papers.
Data collection and analysis
Selection of studies
Papers will be screened according to the title and abstract (where
available) by two review authors independently using the inclu-
sion and exclusion criteria outlined above. Full text papers will be
obtained and screened by two review authors independently. Dis-
agreement will be resolved by discussion or, where disagreements
persist, by a third author, to enable a consensus to be reached.
Where there are multiple publications from the same study, or the
same city or region, all published papers will be selected and data
extracted from the study with the greatest number of outcome
events, i.e. HCV seroconversions.
Data extraction and management
Data will be extracted by one author using a data extraction form
inExcel. For 10%of included studies, data will be double extracted
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by a second author in order to assess the accuracy of data extraction.
Prior to extraction, the data extraction form will be piloted by two
review authors to assess its suitability for the capture of study data
and assessment of quality. Data to be extracted include:
• Lead author, review title or unique identifier and date
• Eligibility for inclusion
• Reasons for exclusion
• Study aim(s)
• Study design (included sampling methods, participant and
attrition rate)
• Study location
• Study setting
• Proportion of participants who are opiate injectors
• Proportion of participants who are stimulant injectors
• Definition of exposure (recency of injecting)
• Intervention (NSP provision; number of needles
distributed; frequency of injection; methadone maintenance
therapy or buprenorphine maintenance treatment; delivery (e.g.
continuous versus interrupted treatment); duration; dose)
• Additional interventions or incentives provided alongside
NSP/OST
• Participants (number in each intervention group; age,
gender and ethnicity)
• Duration of follow up in each treatment arm
• Outcome measure (HCV seroconversion) overall and by
NSP and OST exposure
• Unadjusted and adjusted effect size (incidence rate ratio
(IRR); odds ratio (OR); hazard ratio (HR) and precision (e.g.
95% confidence interval (CI))
• Confounding factors used to adjust effect estimates
including high-risk behaviours (injecting risk behaviours,
frequency of injection, homelessness, experience of prison,
duration of injection, or age, poly drug use)
• Background prevalence of HCV in the population
• Any other comments
Assessment of risk of bias in included studies
The ’Risk of bias’ assessment for RCTs will be performed using the
criteria recommended in the Cochrane Handbook (Higgins 2011).
The recommended approach is a two-part tool, addressing seven
specific domains, namely sequence generation and allocation con-
cealment (selection bias), blinding of participants and providers
(performance bias), blinding of outcome assessor (detection bias),
incomplete outcome data (attrition bias), selective outcome re-
porting (reporting bias) and other source of bias. The first part of
the tool involves describing what was reported to have happened
in the study. The second part of the tool involves assigning a judge-
ment relating to the risk of bias for that entry, in terms of low, high
or unclear risk. To make these judgments we will use the criteria
indicated by the Handbook, adapted to the addiction field. See
Appendix 3 for details. Assessment of risk of bias for unpublished
estimates will be made by referring to the study methods in the
corresponding published paper.
We will assess the risk of bias in non-randomised studies using a
pilot version of a tool in development by Methods Groups of the
Cochrane Collaboration (Sterne 2013). This will be undertaken
as part of the formal piloting of the tool, in collaboration with
its developers. The tool is an extension of the existing tool for
assessing risk of bias in randomised trials (Higgins 2011).
It is composed of six domains, two concerning the pre-intervention
phase:
1. bias due to baseline confounding
2. bias in selection of participants into the study
and four the post-intervention phase:
1. bias due to departures from intended interventions
(performance bias)
2. bias due to missing data (attrition bias)
3. bias in measurement of outcomes or Interventions
(detection bias)
4. bias in selection of the reported results (outcome reporting
bias).
If the pilot version of the tool changes during the course of the
review, we may update our ’Risk of bias’ assessments accordingly.
Grading of evidence
We will assess the overall quality of the evidence for the pri-
mary outcome using the GRADE system. TheGrading of Recom-
mendation, Assessment, Development and Evaluation (GRADE)
Working Group developed a system for grading the quality of ev-
idence (GRADE 2004; Guyatt 2008; Guyatt 2011; Schünemann
2006) which takes into account issues not only related to internal
validity but also to external validity, such as directness of results.
The ’Summary of findings’ tables present the main findings of a
review in a transparent and simple tabular format. In particular,
they provide key information concerning the quality of evidence,
themagnitude of effect of the interventions examined and the sum
of available data on the main outcomes.
TheGRADE systemuses the following criteria for assigning grades
of evidence:
High: further research is very unlikely to change our confidence in
the estimate of effect. Moderate: further research is likely to have
an important impact on our confidence in the estimate of effect
and may change the estimate. Low: further research is very likely
to have an important impact on our confidence in the estimate of
effect and is likely to change the estimate. Very low: any estimate
of effect is very uncertain.
Grading is decreased for the following reasons: Serious (-1) or very
serious (-2) limitation to study quality. Important inconsistency (-
1). Some (-1) ormajor (-2) uncertainty about directness. Imprecise
or sparse data (-1). High probability of reporting bias (-1).
Grading is increased for the following reasons: Strong evidence
of association - significant relative risk of > 2 (< 0.5) based on
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consistent evidence from two or more observational studies, with
no plausible confounders (+1). Very strong evidence of association
- significant relative risk of > 5 (< 0.2) based on direct evidence
with no major threats to validity (+2). Evidence of a dose response
gradient (+1). All plausible confounders would have reduced the
effect (+1).
Measures of treatment effect
Dichotomous outcomes will be analysed by calculating the rela-
tive risk (RR) for each study, with the uncertainty in each result
expressed with 95% confidence intervals (CI). Continuous out-
comes will be analysed by calculating the mean difference (MD)
or the standardised mean difference (SMD) with 95% CI.
Dealing with missing data
Study authors will be contacted if studies provide data regarding
use of NSP or the impact of drug treatment onHCV transmission,
but where insufficient detail is provided regarding the precise form
of treatment provided. We will also contact study authors if HCV
incidence data are reported but no data regarding drug treatment
or NSP are provided. If missing data cannot be obtained, studies
will be excluded from analysis.
Assessment of heterogeneity
Heterogeneity will be examined via inspection of the forest plot
and by aChi2 test to demonstrate whether the observed differences
in results are compatible with chance alone. The I2 statistic will
be calculated to examine the percentage of variability that is due
to heterogeneity rather than to sampling error. Heterogeneity will
be explored through sensitivity and subgroup analysis
Assessment of reporting biases
Funnel plots will be used to plot the study effect size against sample
size to assess publication bias.
Data synthesis
Since there may be significant heterogeneity between studies, a
description and summary of the findings of included studies will
be included in the review. Where studies are sufficiently similar,
we will carry out meta-analysis. The appropriate method of meta-
analysis will depend on the nature of the outcome data (dichoto-
mous, ordinal, continuous, time-to-event etc.)
A random-effects model will be used because some degree of het-
erogeneity is expected.Wewill conduct subgroup analysis by study
design if there is a great variation in study design.
Subgroup analysis and investigation of heterogeneity
Where sufficient data are available, wewill perform subgroup anal-
yses and meta-regression models to compare outcomes by:
• Age, gender and/or ethnicity
• Frequency of injecting and main drug injected
• Dose, duration, and/or delivery of NSP/ OST (i.e.
continuous or interrupted treatment)
• Type of OST provided (i.e. methadone maintenance
therapy or buprenorphine maintenance treatment)
• Type of NSP (fixed site or mobile)
Sensitivity analysis
We will assess whether meta-analyses are subject to small study
bias by carrying out fixed-effect and random-effectsmeta-analyses.
We will exclude studies that are at critical risk of bias. We will
also use sensitivity analysis to determine to what extent the overall
intervention effect is changed by the inclusion of: studies at severe
or unclear risk of bias; studies that did not adjust for confounders;
studies thatmeasured incidence rate ratio; and studies that assessed
the impact of intervention at baseline only.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy 1
1. Needle-Exchange Programs/
2. Community pharmacy services/
3. ((needle* or syringe* or inject*) adj3 exchange).ab,ti.
4. Harm Reduction/
5. (harm adj reduc*).ab,ti.
6. ((needle* or syringe* or inject*) adj3 (suppl* or access* or provision or provid* or distribut* or dispens* or pack*)).ab,ti.
7. ((needle* or syringe* or inject*) adj3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or pharmacy
or pharmacies or unit or units or room*)).ab,ti.
8. ((needle* or syringe* or inject* or slot or dispensing or vending) adj3 (machine* or (peer adj distrib*))).ab,ti.
9. or/1-8
10. Substance Abuse, Intravenous/
11. (substance$ or drug$).ab,ti.
12. (abuse$ or depend$ or use$ or misus$ or addict$).ab,ti.
13. (inject$ or intravenous).ab,ti.
14. 10 or (11 and 12) or (11 and 13)
15. opiate substitution treatment/
16. methadone/
17. buprenorphine/
18. (((substitut* or maint*) adj2 (treatment or therapy)) or methadone or buprenorphine or subutex or suboxone).ab,ti.
19. or/15-18
20. exp Hepatitis C/
21. (hepatitis-c or or hep c or hcv).ab,ti.
22. 20 or 21
23. (9 or 19) and 14 and 22
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Appendix 2. MEDLINE search strategy 2
1. Substance Abuse, Intravenous/
2. (substance$ or drug$).ab,ti.
3. (abuse$ or depend$ or use$ or misus$ or addict$).ab,ti.
4. (inject$ or intravenous).ab,ti.
5. 1 or (2 and 3) or (2 and 4)
6. exp Hepatitis C/
7. (hepatitis-c or hcv).ab,ti.
8. (HCV adj2 seroconvers$).ti,ab.
9. (HCV adj2 transmission).ti,ab.
10. or/6-9
11. exp Cohort Studies/
12. exp Longitudinal Studies/
13. (prospective or longitudinal or cohort).ti,ab.
14. or/11-13
15. 5 and 10 and 14
16. Animals/
17. 15 not 16
Appendix 3. Criteria for risk of bias assessment for RCTs
Item Judgment Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal alloca-
tion: central allocation (including telephone, web-based, and pharmacy-
controlled, randomisation); sequentially-numbered drug containers of
identical appearance; sequentially-numbered, opaque, sealed envelopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following method was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
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(Continued)
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3. Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding;
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
4. Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers ensured and unlikely that the
blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
5. Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
6.Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
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(Continued)
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
7. Incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or drop out
Low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
comparedwith observed event risk not enough tohave a clinically-relevant
impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans or
standardised difference in means) among missing outcomes not enough
to have a clinically-relevant impact on observed effect size;
Missing data have been imputed using appropriate methods;
All randomised patients are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across in-
tervention groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough to
induce clinically relevant bias in observed effect size;
‘As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop out not reported for each group)
8 Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way;
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)
11Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject
drugs (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
High risk Not all of the study’s pre-specified primary outcomes have been reported;
One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not pre-specified;
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Unclear risk Insufficient information to permit judgement of low or high risk
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